News
Novo Nordisk rebounds from 2024 lows as GLP-1 supply issues ease, partnerships expand, and valuation turns attractive. Find ...
CHICAGO -- An investigational, oral small-molecule GLP-1 receptor agonist improved glycated hemoglobin levels in adults with ...
Overweight patients given an experimental weight loss drug being developed by China's Sciwind Biosciences lost an average of ...
More than 90% of patients achieved clinically meaningful weight reduction compared to placebo in a phase 3 trial of ecnoglutide.
1d
MedPage Today on MSNGLP-1 Drugs Can Be Used First for Weight Loss, Says American College of CardiologyWith semaglutide and tirzepatide dosed once weekly, their estimated average yearly costs in the U.S. are $14,080 and $8,126, ...
Glucagon-Like-Peptide-1 Agonists, like Ozempic, have become extremely popular for weight loss. Here are some of the side ...
1d
Flow Space on MSNWhat the Latest GLP-1 Guidelines Could Mean for Midlife WomenIn a move that could reshape how doctors approach both weight and heart health, the American College of Cardiology (ACC) ...
A new study reports that people taking GLP-1 drugs in daily life don’t lose as much weight as those in clinical trials who ...
A diabetes medication that lowers brain fluid pressure has cut monthly migraine days by more than half, according to a new ...
That is according to the findings of a study presented on Friday at the European Academy of Neurology congress. The pilot ...
GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.
Ohio to end GLP-1 drug coverage for most state workers without diabetes, citing soaring Medicaid costs and rising demand for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results